VIR 280K $ YOLO ahead of Phase 3 results
$VIR
AI SUMMARY — The poster is making a large $280K bet on Vir Biotechnology (VIR) ahead of Phase 3 clinical trial results, expecting positive outcomes to drive significant stock appreciation. Key risks include the uncertainty of Phase 3 data, potential trial failure, regulatory delays, and the volatile nature of biotech stocks during clinical catalysts.
| TICKER | VIR |
USER | u/ElectricalJeweler587 |
| RATING |
BULLISH |
ENTRY |
$10.47
|
| POSITION |
955 sh
SYN
|
BOOK VAL |
$10000.00 |
| CURRENT |
$10.47 |
P&L % |
+0.00%
|
| CURR VAL |
$10000.00 |
P&L $ |
+0.00
|